Hussain SA - Search Results

1

Recent advances and future directions in the management of metastatic renal cell carcinoma.

Ansari J, Glaholm J, McMenemin R, James ND, Hussain SA. Ansari J, et al. Among authors: hussain sa. Anticancer Agents Med Chem. 2010 Mar;10(3):225-35. doi: 10.2174/1871520611009030225. Anticancer Agents Med Chem. 2010. PMID: 20184547 Review.

2

Hepatocellular carcinoma.

Hussain SA, Ferry DR, El-Gazzaz G, Mirza DF, James ND, McMaster P, Kerr DJ. Hussain SA, et al. Ann Oncol. 2001 Feb;12(2):161-72. doi: 10.1023/a:1008370324827. Ann Oncol. 2001. PMID: 11300318 Free article. Review.

3

A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer.

Hussain SA, Moffitt DD, Glaholm JG, Peake D, Wallace DM, James ND. Hussain SA, et al. Ann Oncol. 2001 Jul;12(7):929-35. doi: 10.1023/a:1011133820532. Ann Oncol. 2001. PMID: 11521797 Free article. Clinical Trial.

4

Organ preservation strategies in bladder cancer.

Hussain SA, James ND. Hussain SA, et al. Expert Rev Anticancer Ther. 2002 Dec;2(6):641-51. doi: 10.1586/14737140.2.6.641. Expert Rev Anticancer Ther. 2002. PMID: 12503210 Review.

5

Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder.

Hussain SA, Ganesan R, Hiller L, Murray PG, el-Magraby MM, Young L, James ND. Hussain SA, et al. Br J Cancer. 2003 Feb 24;88(4):586-92. doi: 10.1038/sj.bjc.6600765. Br J Cancer. 2003. PMID: 12592374 Free PMC article.

6

BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder.

Hussain SA, Ganesan R, Hiller L, Cooke PW, Murray P, Young LS, James ND. Hussain SA, et al. Oncol Rep. 2003 May-Jun;10(3):571-6. Oncol Rep. 2003. PMID: 12684626

7

The systemic treatment of advanced and metastatic bladder cancer.

Hussain SA, James ND. Hussain SA, et al. Lancet Oncol. 2003 Aug;4(8):489-97. doi: 10.1016/s1470-2045(03)01168-9. Lancet Oncol. 2003. PMID: 12901963 Review.

8

Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder.

Hussain SA, Palmer DH, Ganesan R, Hiller L, Gregory J, Murray PG, Pastorek J, Young L, James ND. Hussain SA, et al. Oncol Rep. 2004 May;11(5):1005-10. Oncol Rep. 2004. PMID: 15069539

9

Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer.

Hussain SA, Stocken DD, Peake DR, Glaholm JG, Zarkar A, Wallace DM, James ND. Hussain SA, et al. Br J Cancer. 2004 Jun 1;90(11):2106-11. doi: 10.1038/sj.bjc.6601852. Br J Cancer. 2004. PMID: 15150587 Free PMC article. Clinical Trial.

10

A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer.

Hussain SA, Stocken DD, Riley P, Palmer DH, Peake DR, Geh JI, Spooner D, James ND. Hussain SA, et al. Br J Cancer. 2004 Aug 31;91(5):844-9. doi: 10.1038/sj.bjc.6602112. Br J Cancer. 2004. PMID: 15292922 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

845 results

Search Page

Filters